STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Q1 2024 Results Conference Call May 2, 2024 4:30 PM ET

Company Participants

Dolev Rafaeli - Chief Executive Officer
Chris Lesovitz - Chief Financial Officer

Conference Call Participants

Jeffrey Cohen - Ladenburg Thalmann & Co.

Operator

Ladies and gentlemen, thank you for standing by. Good afternoon, and welcome to the STRATA Skin Sciences Inc. First Quarter of 2024 Financial Results and Corporate Update Conference Call. [Operator Instructions] A webcast replay of the call will be available approximately one hour after the end of the call through November 15, 2024.

And with that, I'd like to turn the call over to [Indiscernible]. Please go ahead.

Unidentified Company Representative

Good afternoon, and thank you for participating in today's conference call. Earlier this afternoon, the company released its financial results for the quarter ended March 31, 2024. A copy of that press release can be found on the company's website at www.strataskinsciences.com under the Investors tab.

Joining me on today's earnings call from STRATA Skin Sciences Management Team are Dr. Dolev Rafaeli, Chief Executive Officer; and Chris Lesovitz, Chief Financial Officer. During this call, management will be making forward-looking statements, including statements that address STRATA Skin Sciences expectations for future performance or operational results. Forward-looking statements involve risks and other factors that may cause actual results to differ materially from those statements.

For more information about these risks, please refer to the risk factors described in STRATA Skin Sciences most recently filed annual report and Form 10-K and subsequent periodic reports filed with the SEC and STRATA Skin Sciences press release that accompanies this call, particularly the cautionary statements in it. The content of this call contains time sensitive information that is accurate only as of today, May 15, 2024, except as required by law STRATA Skin Sciences disclaims any obligation to publicly update or revise any information to reflect events or circumstances that occur after this call.

It's now my pleasure to turn the call over to CEO Dr. Dolev Rafaeli.

Dolev Rafaeli

Thank you Joey, and good afternoon for everyone on the call.

During the first quarter, we continued to execute on the multifaceted turnaround strategy introduced when I was appointed CEO late last year. Clinical results using XTRAC are proven across the hundreds of thousands of patients treated for psoriasis, vitiligo, and eczema. And our strategy primarily focused on adjusting our XTRAC device placements and increasing our DTC marketing to drive XTRAC device utilization and recurring revenue per device over the coming quarters across our domestic and store base of approximately 900 devices.